Gordon Lam is a Rheumatology/Immunology physician affiliated with Atrium Health Wake Forest Baptist. OpenAlex indexes 16 publications with 1,239 citations (h-index 11); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
801 E Morehead St Ste 100
Charlotte, NC 282023195
Telephone
704-342-0252Provider last certified this registry record 2 Jan 2026.
Clinical trials
- Prediction of Methotrexate Response - A Pilot Study
Sponsor: Wake Forest University Health Sciences
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
28 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year202597 payments$111,825openpaymentsdata.cms.gov ↗
- AstraZeneca Pharmaceuticals LPProgram year202589 payments$79,949openpaymentsdata.cms.gov ↗
- Amgen Inc.Program year2025101 payments$74,629openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
75.7%TNF inhibitor39.2%Certolizumab pegol57%Golimumab34%Infliximab8%Enbrel Sureclick0%Enbrel0%Part D + Part B<11 patientsInterleukin-6 Receptor Antagonist28.1%Tocilizumab100%Actemra0%Part D + Part B<11 patients+ 6 more classes in this area
Musculoskeletal
21.1%Other drugs affecting bone structure and mineralization14.8%Romosozumab-aqqg100%Part B, office-administered≥20 patientsRANK Ligand Inhibitor5.8%Denosumab100%Part B, office-administered≥68 patients+ 6 more classes in this area
Dermatology
1.7%Corticosteroid1.7%Methylprednisolone acetate61%Methylprednisolone sodium succinate33%Triamcinolone acetonide7%Part B, office-administered≥23 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab
Alimentary Pharmacology & Therapeutics
2018 - Efficacy and safety of etanercept in the treatment of scleroderma-associated2017
Similar KOLs
Other experts from the same institution or the same specialty.
David Herrington, MD
Atrium Health Wake Forest Baptist
Bruce Lessey, MD
Atrium Health Wake Forest Baptist
David Hurd, MD
Atrium Health Wake Forest Baptist
Kevin High, MD
Atrium Health Wake Forest Baptist
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”